No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 77 contracts
Samples: Purchase Agreement (CymaBay Therapeutics, Inc.), Underwriting Agreement (NEUROONE MEDICAL TECHNOLOGIES Corp), Purchase Agreement (CymaBay Therapeutics, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has not effected any sales of Common Stock which are required to be disclosed in response to Item 701 of Regulation S-K under the Act which have not been so disclosed in the Registration Statement.
Appears in 67 contracts
Samples: Underwriting Agreement (Processa Pharmaceuticals, Inc.), Underwriting Agreement (Fresh Vine Wine, Inc.), Underwriting Agreement (Fresh Grapes, LLC)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 28 contracts
Samples: Underwriting Agreement (aTYR PHARMA INC), Purchase Agreement (aTYR PHARMA INC), Underwriting Agreement (Miromatrix Medical Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has not effected any sales of Common Stock which are required to be disclosed in response to Item 701 of Regulation S-K under the Act which have not been so disclosed in the Registration Statement.
Appears in 27 contracts
Samples: Underwriting Agreement (Aziyo Biologics, Inc.), Underwriting Agreement (Orthopediatrics Corp), Purchase Agreement (Progenity, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 12 contracts
Samples: Underwriting Agreement (OptiNose, Inc.), Underwriting Agreement (Lantronix Inc), Underwriting Agreement (Streamline Health Solutions Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has not effected any sales of securities which are required to be disclosed in response to Item 701 of Regulation S-K under the Securities Act which have not been so disclosed in the Registration Statement.
Appears in 7 contracts
Samples: Underwriting Agreement (Direct Digital Holdings, Inc.), Underwriting Agreement (Direct Digital Holdings, Inc.), Underwriting Agreement (Direct Digital Holdings, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesShares.
Appears in 7 contracts
Samples: Underwriting Agreement (MamaMancini's Holdings, Inc.), Purchase Agreement (Aravive, Inc.), Underwriting Agreement (Immucell Corp /De/)
No Market Stabilization or Manipulation. The Company has not taken taken, and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 5 contracts
Samples: Purchase Agreement (Zosano Pharma Corp), Purchase Agreement (Zosano Pharma Corp), Purchase Agreement (Zosano Pharma Corp)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has not effected any sales of Common Stock which are required to be disclosed in response to Item 701 of Regulation S-K under the Securities Act which have not been so disclosed in the Registration Statement.
Appears in 5 contracts
Samples: Underwriting Agreement (Surgalign Holdings, Inc.), Underwriting Agreement (ViewRay, Inc.), Underwriting Agreement (ViewRay, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesSecurities in violation of applicable law.
Appears in 5 contracts
Samples: Underwriting Agreement (Microvision, Inc.), Underwriting Agreement (Microvision, Inc.), Underwriting Agreement (Microvision, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesShares, and has not effected any sales of Common Stock which are required to be disclosed in response to Item 701 of Regulation S-K under the Act which have not been so disclosed in the Registration Statement.
Appears in 5 contracts
Samples: Underwriting Agreement (Naked Brand Group Inc.), Underwriting Agreement (Naked Brand Group Inc.), Underwriting Agreement (BioPharmX Corp)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 4 contracts
Samples: Purchase Agreement (POINT Biopharma Global Inc.), Purchase Agreement (Apollo Endosurgery, Inc.), Purchase Agreement (Alcobra Ltd.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has not effected any sales of Common Stock which are required to be disclosed in response to Item 701 of Regulation S‑K under the Act which have not been so disclosed in the Registration Statement.
Appears in 4 contracts
Samples: Underwriting Agreement (Viking Therapeutics, Inc.), Underwriting Agreement (Viking Therapeutics, Inc.), Underwriting Agreement (Viking Therapeutics, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not taketaken, directly or indirectly, any action designed to or which might that could reasonably be expected to cause or result in, or which has constituted, the in any stabilization or manipulation of the price of any security of the Company to facilitate in connection with the sale or resale offering of the SecuritiesADSs.
Appears in 2 contracts
Samples: Underwriting Agreement (Innocoll AG), Underwriting Agreement (Innocoll GmbH)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might would reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesShares.
Appears in 2 contracts
Samples: Subscription Agreement (Usa Technologies Inc), Underwriting Agreement (Catalyst Biosciences, Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might that could reasonably be expected to cause or result in, or which has constituted, the in any stabilization or manipulation of the price of any security of the Company to facilitate Shares or the sale or resale of the SecuritiesADSs.
Appears in 2 contracts
Samples: Underwriting Agreement (Materialise Nv), Underwriting Agreement (Materialise Nv)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constitutedconstitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 1 contract
Samples: Underwriting Agreement (Gemphire Therapeutics Inc.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which that might reasonably be expected to cause or result in, or which that has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
Appears in 1 contract
No Market Stabilization or Manipulation. The Company has not taken taken, and will not take, directly or indirectly, any action designed to or which might that could reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesShares.
Appears in 1 contract
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, other than the share repurchases as described in the Time of Sale Disclosure Package and the Offering Memorandum.
Appears in 1 contract
Samples: Purchase Agreement (Cinedigm Corp.)
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities..
Appears in 1 contract
No Market Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the SecuritiesSecurities or the Warrant Shares.
Appears in 1 contract
No Market Stabilization or Manipulation. The Company has not taken and will not taketaken, directly or indirectly, any action designed to or which might that could reasonably be expected to cause or result in, or which has constituted, the in any stabilization or manipulation of the price of any security of the Company to facilitate in connection with the sale or resale offering of the SecuritiesShares.
Appears in 1 contract
